SHIKARI® Q-RITUX
The Matriks Biotek Rituximab Enzyme-LinkedImmuno-Sorbent-Assay (ELISA) Kit is intended for the quantitative determination of Rituximab (Rituxan®, Mabthera®)* in serum and plasma. It is for professional use only.

SHIKARI® S-ATR
Required Volume 
Total Time 
Sample
Sample Number
Detection Limit 
Spike Recovery 
Shelf Life
10ul
135 min
Serum, plasma
96
3ng/mL
85-115%
1 year
The Matriks Biotek anti-Rituximab Enzyme-Linked-Immuno-Sorbent-Assay (ELISA) Kit is intended for the qualitative determination of antibodies to Rituximab (Rituxan®, Mabthera®) in serum and plasma.
Calibration Curve
SHIKARI® Q-RITUX & S-ATR
Rituximab (Rituxan®, Mabthera ®)
Enzyme immunoassay for the quantitative determination of Rituximab (Rituxan®, Mabthera®) in serum and plasma
Enzyme immunoassay for the determination of antibodies to Rituximab (Rituxan®, Mabthera®) in serum and plasma
Required Volume 
Total Time 
Sample
Sample Number
Detection Limit 
Spike Recovery 
Shelf Life
20ul
140 min
Serum, plasma
96
30ng/ml
85-115%
1 year
RIT-FD-RM: $910.00                                                                    Lead time: 1-2 weeks
RIT-QLS-RM (w/o Confirmation): $910.00
RIT-QNS-RM (w/ Confirmation): $945.00            
Calibration Curve
RIT-QLS-RM


RIT-QNS-RM
* Rituxan® is a registered trademark of Biogen Idec, Inc., Mabthera® is a registered trademark of Roche, Inc.
.....................................................
Lead time: 1-2 weeks
.....................................................
Drug Measurement
Anti-drug Antibody Measurement
Quantitative
Quantitative
Qualitative
Rituximab (Rituxan®, Mabthera®)
Anti Cancer Drugs
Q-RITUX
(Free)

#RIT-FD-RM
S-ATRv1
(Free)

#RIT-QLS-RM
S-ATRv2
(Free)

#RIT-QNS-RM0201
Iwai North America Inc.

541 Taylor Way Suite# 4
 San Carlos, CA 94070
 Phone : (650) 486-1541
Fax : (650) 394-8638
 Open weekdays 9 AM-6 PM (PST)
.........................................................................................................................................................................................................................................................